Good resultWith good results regarding the reduction of lung inflamation on COVID patients using FSD201 we will see a big jump in the stock. We will have COVID for long or other respiratory virus outbreaks in the future, if clinical trials goes well they can sell the drug to a big pharma, that will be great for you.